1 / 3

Background HAART has improved AIDS-associated morbidity and mortality

liam
Download Presentation

Background HAART has improved AIDS-associated morbidity and mortality

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH. • Background • HAART has improved AIDS-associated morbidity and mortality • Given the bimodal mortality distribution in HIV-infected children, it is important to evaluate temporal effects of HAART among a pure birth cohort with long-term, prospective follow-up. • Methods • CDC-sponsored multi-center, prospective birth cohort study of HIV-exposed infants enrolled 1986-1999 to monitor MTCT and pediatric HIV progression. • HIV-infected children followed through 4/04 • Average annual mortality calculated for no/mono-therapy (≤12/31/90), mono/dual-therapy (1/1/91-12/31/96) and HAART eras (≥1/1/97) • Mortality trends evaluated using survival analysis and Poisson regression • Extended Cox proportional-hazards regression models (Cox PH) estimated the effect of HAART on mortality

  2. Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH. • Results • Among 364 children, 98 died 61 were < 2 y/o; 18 more were between 2 – 3 y/o. • Ten-year survival of those who ever received HAART and of non-HAART recipients was 94% and 45% (P<0.05) Survival probability among HAART recipients (defined by age of initiation of HAART) vs. non-recipients

  3. Trends in Mortality in the Pre- & Post-HAART Eras among HIV-Infected Children in the U.S. Perinatal AIDS Collaborative Transmission Study (PACTS) (1986-2004)B. Kapogiannis*1, M. Soe2, S. Nesheim2, EJ. Abrams3, J. Farley4, P. Palumbo5, LJ. Koenig2, and M. Bulterys2National Institute of Child Health and Human Development (NICHD) / National Institutes of Health (NIH) 1, Bethesda, MD; Centers for Disease Control & Prevention (CDC)2, Atlanta, GA; Harlem Hospital, Columbia University3, NYC, NY; University of Maryland4, Baltimore, MD and Dartmouth College5, Hanover, NH. • Results (cont’d) • HAART-associated declines in mortality remained significant after controlling for birth year, CD4%, anthropometrics (HAZ & WAZ) and maternal CDC classification (Cox PH model, HR=0.25: 95%CI 0.08-0.76) • Conclusions • A significant decrease in annual mortality and a prolongation in survival were seen among HAART recipients in this U.S. perinatal cohort of HIV-infected children • Advances in antiretroviral therapy led to commensurate improvements in crude annual mortality rates (Log-Rank test P<0.05) • Using Poisson regression to adjust for gender, race, prematurity, era-entry age, AZT prophylaxis, maternal AIDS class and IVDU hx, the mortality rate ratios in the no/mono- and mono/dual- therapy eras were ~30-fold (P<0.01) and ~9-fold(P<0.01) higher, respectively, than in the HAART era

More Related